Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Stresses Data Comparison In Push For Top Interventional Cardiology Spot

This article was originally published in The Gray Sheet

Executive Summary

Price premiums and increased procedures related to drug-coated stents are expected to more than double the worldwide interventional cardiology market to $9.2 bil. over the next six years, Johnson & Johnson/Cordis predicts.

You may also be interested in...



SIRIUS Cost Data Suggests Higher Inpatient Payment Level For Eluting Stents

Cost-effectiveness data collected by Johnson & Johnson/Cordis from trials of its Cypher sirolimus-eluting coronary stent will justify assigning the device to a new diagnosis-related group (DRG) in time for the expected 2003 U.S. launch, according to Cordis

SIRIUS Cost Data Suggests Higher Inpatient Payment Level For Eluting Stents

Cost-effectiveness data collected by Johnson & Johnson/Cordis from trials of its Cypher sirolimus-eluting coronary stent will justify assigning the device to a new diagnosis-related group (DRG) in time for the expected 2003 U.S. launch, according to Cordis

Novoste Looking For “Deal-Maker” As CEO Hawkins Moves To Medtronic

Novoste will shift focus from leveraging core technologies and building a sales infrastructure to diversification and growth following the departure of CEO and President Bill Hawkins in mid-January to head Medtronic's vascular unit, Medtronic AVE

UsernamePublicRestriction

Register

LL1135009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel